TriangleASP5541 (NCT07005154)
ASP5541 trial for Prostate Cancer (NCT07005154). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic prostate adenocarcinoma. Main cohorts require no prior androgen-receptor pathway inhibitor.
The idea: ASP5541 is a muscle injection every 12 weeks, designed to reduce testosterone production. Researchers compare it with daily oral abiraterone. Castration-resistant cohorts use a steroid with either drug; hormone-sensitive cohorts compare steroid-free ASP5541 with abiraterone plus a steroid. Standard hormone suppression continues. A separate Japanese cohort assesses ASP5541 with steroids.
This phase 2 study plans 218 patients. Astellas sponsors it; 12 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.